Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unifuzol in Peripheral Arterial Disease
NCT03861416Phase 2Completed
- Sponsor
- POLYSAN
- Start
- Mar 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of arginine sodium succinate in Peripheral Arterial Disease (PAD) (3 arms), sponsored by POLYSAN. Primary endpoint: Maximum walking distance at Day 30. Started Mar 2018; status: completed.
02
Drugs
arginine sodium succinate
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03861416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861416.